2022 World Conference on Lung Cancer (ePosters)-EP01.01-005. Increased Levels of mRNAs and miRNAs Associated with Imminent and Advanced Lung Cancer

Pdf Summary

A study was conducted to identify potential candidate markers for lung cancer (LC) at diagnosis and before diagnosis. In the LC diagnosis cohort, gene expression in whole blood and miRNA expression in serum were compared between confirmed LC cases and controls with negative LC diagnostic evaluations. The study also evaluated the associations of candidate markers with LC survival using statistical models. In the cohort prior to LC diagnosis, 14 mRNA and 9 miRNA candidate markers were assessed in blood samples collected up to 8 years before LC diagnosis in future LC cases and matched controls. The study found increased levels of mRNAs and miRNAs associated with imminent and advanced lung cancer. Some of the most promising candidate markers included miR-320b, miR-320c, miR-320d, ANXA3, ARG1, and HP.<br /><br />The accessibility of peripheral blood as a source of biomarkers makes it a potentially useful tool for early LC detection. Biomarkers in blood prior to LC diagnosis could be used to identify individuals with increased LC risk, improving sensitivity and specificity in LC screening programs. The study identified 3,000 differentially expressed genes and 70 differentially expressed miRNAs in LC cases compared to controls at diagnosis. Among these, miR-320b, miR-320c, miR-320d, ANXA3, ARG1, and HP were found to be the most promising candidate markers of LC in blood. High expression of these markers was associated with poor survival, particularly in late-stage LC cases.<br /><br />Before LC diagnosis, the expression of miR-320c, miR-320d, and ARG1 increased up to two years prior to LC diagnosis in advanced LC cases. Elevated levels of these markers were identified as the most promising candidate markers for imminent and advanced lung cancer in blood. These markers could potentially have clinical impact by indicating individuals with increased LC risk for inclusion in screening programs or more frequent follow-up. The findings provide valuable insights into the development of biomarkers for early detection and improved management of lung cancer.

Asset Subtitle

Ilona Urbarova, Norway

Meta Tag

Speaker Ilona Urbarova, Norway

Topic Early Detection and Screening - Biomarkers

Keywords

lung cancer

candidate markers

gene expression

miRNA expression

diagnosis cohort

LC survival

mRNA

miRNA

blood samples

LC risk